Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859012 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CES2CES1KEAP1TSHR | |
| SCHEMBL2859011 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CES2CES1KEAP1TSHR | |
| SCHEMBL2871203 | 0.88 | CES2 (0.40) | ALDH1A1CES2CES1KEAP1TSHR | |
| SCHEMBL2871207 | 0.88 | CES2 (0.40) | ALDH1A1CES2CES1KEAP1TSHR | |
| SCHEMBL2872072 | 0.88 | CES2 (0.40) | ALDH1A1CES2CES1KEAP1TSHR | |
| SCHEMBL2867482 | 0.85 | L3MBTL1 (0.45) | ALDH1A1CES2CES1KEAP1TSHR | |
| SCHEMBL2867478 | 0.85 | L3MBTL1 (0.45) | ALDH1A1CES2CES1KEAP1TSHR | |
| SCHEMBL2869745 | 0.85 | L3MBTL1 (0.45) | ALDH1A1CES2CES1KEAP1TSHR | |
| SCHEMBL2515076 | 0.85 | NPC1 (0.42) | ALDH1A1CES2CES1KEAP1RAB9A | |
| SCHEMBL2865878 | 0.85 | ALDH1A1 (0.41) | ALDH1A1CES2CES1KEAP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659409-B2 | 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20050107621-A1 | 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1486493-A1 | 3-HYDROXY-3-(2-THIENYL)PROPIONAMIDE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING 3-AMINO-1-(2-THIENYL)-1-PROPANOL COMPOUND THEREFROM | Mitsubishi Chemical Corporation (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107621-A1 | 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same | APEH, AADAC, KMO | ALDH1A1 174/4885CES2 719/4885CES1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.